查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球预测诊断市场
市场调查报告书
商品编码
1176560

2023-2030 年全球预测诊断市场

Global Predictive Diagnostics Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

预测诊断的全球市场预计在预测期内 (2023-2030) 将显着增长。

预测性诊断使用定制数据和一套诊断工具来提供准确、实时的见解并识别潜在问题。 通过整合分子创新、基因组学应用和快速研发流程，预测诊断可以影响运营并带来可衡量的进步。

市场动态

全球预测诊断市场受到技术进步、研发中越来越多地采用预测诊断、与生活方式相关的疾病日益流行以及健康意识不断提高的推动。

预测诊断在医疗保健领域的优势不断增强，推动了市场增长

诊断领域的技术进步将在预测期内推动市场。 根据飞利浦 2020 年 6 月的一份报告，医疗保健领域的预测分析可以检测重症监护病房和普通病房患者身体退化的早期迹象，识别家中的高危患者，并减少再次入院率。并有助于防止可避免的医疗停机时间设备。 预测诊断结合来自多个来源的数据，例如电子医院病历、跌倒检测吊坠和医疗呼叫服务使用历史，以识别未来 30 天内有救护车风险的老年人。我可以。 预测性诊断使医疗保健提供者能够在跌倒和其他医疗并发症发生之前接触到老年人，防止不必要的再入院，并减少运输、急救和康復成本。

此外，市场参与者正在应用产品发布和合作等市场策略来扩展业务。 例如，2021 年 10 月，专注于体外诊断的法国跨国生物技术公司生物梅里埃 (bioMerieux) 推出了其关于食品安全和食品质量的新主张——预测诊断。 同样在 2022 年 9 月，QIAGEN 和 Neuron23 Inc.（一家专注于为遗传定义的神经系统疾病和免疫疾病设计精准药物的生物技术组织）宣布，Neuron23 的针对帕金森病的脑穿透富含亮氨酸重复序列。同意创建激□的伴随诊断（ LRRK2) 抑製剂。 根据协议条款，QIAGEN 将设计和验证一项临床试验分析，检测 Neuron23 发现的生物标誌物的混合物，这些生物标誌物可预测帕金森病对 LRRK2 抑製剂的反应。 此外，此次合作将支持 Neuron23 候选药物的临床开发，这些候选药物目前处于临床前后期开发阶段。 它还包括随着临床开发的进展开发其他伴随诊断的选项。

缺乏预测诊断测试专业知识阻碍了市场增长

然而，生物标誌物识别慢性退行性疾病的不可靠性以及预测诊断测试专业知识的缺乏将在预测期内限制市场。

COVID-19 影响分析

COVID-19 的出现对全球预测诊断市场产生了积极影响。 根据 2020 年发表在 Advances in Biomarker Sciences and Technology 上的一篇文章，生物标誌物在大流行情况下尤为重要，因为它们可以加强新的创新药物和生物製品的开发和批准，特别是在疫苗领域。据说是 生物标誌物很受关注，因为它们描述了特定疾病的可观察特征，并可用于根据其表型或基因型确定最佳治疗方案。 特别是，急性呼吸窘迫综合征 (ARDS) 等呼吸系统疾病的生物标誌物与死亡率增加（IL-8、ICAM-1）和存活率提高（一氧化氮）有关。我知道。 这些生物标誌物在预测未来并发症和疾病严重程度方面具有关键作用，可能是 COVID-19 的有用预后指标。

内容

第 1 章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 慢性病患病率上升
      • 各种癌症的增加
      • 需要及早发现各种遗传疾病
    • 约束因素
      • 不可靠的生物标誌物
      • 缺乏专业知识
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 前驱型
  • 前驱型

第八章应用

  • 心血管疾病
  • 神经系统疾病
  • 遗传病
  • 肿瘤学
  • 其他

第 9 章最终用户

  • 诊断
  • 基因检测机构/诊所
  • 研究和学术机构

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 按类型划分的基准

第12章公司简介

  • Abbott Molecular
    • 公司概况
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Almac Group Ltd.
  • Ambry Genetics Corporation
  • BioGenex
  • Epistem Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Genomic Health, Inc.
  • MDxHEALTH, Inc.
  • Myriad Genetics, Inc.
  • OPKO Health, Inc.
  • Prometheus Laboratories Inc.
  • Proteomics International Laboratories Ltd
  • QIAGEN N.V.

第13章 DataM

简介目录
Product Code: DMCD1123

Market Overview

The Global "Predictive Diagnostics Market" size was valued at US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).

Predictive diagnostics employs customized data and a suite of diagnostic devices to deliver precise, real-time insights and identify potential problems. By integrating molecular innovations, genomics applications, and rapid R&D processes, Predictive diagnostics can assist deliver impactful and measurable advancements to operations.

Market Dynamics

The global predictive diagnostics market is driven by technological advancements, growing adoption of predictive diagnostics in research and development, rising lifestyle disease, and an increasingly health-conscious population.

Increasing benefits of predictive diagnostics in healthcare drives market growth

The technological advancements in diagnostics sectors drive the market in the forecast period. According to the Philips report, June 2020, predictive analytics in healthcare help detect early signs of patient degeneration in intensive care units and general wards, recognize at-risk patients in their residences to prevent hospital readmissions, and prevent avoidable downtime of medical equipment. Predictive diagnostics allows combining data from multiple sources - including hospital-based electronic medical records, fall detection pendants, and the historical use of medical alert services - to identify seniors at risk of emergency transport in the next 30 days. Predictive diagnostics allows healthcare providers to reach out to a senior person before a fall or another medical complication occurs, preventing unnecessary hospital readmissions and reducing transportation, acute care, and rehabilitation costs.

In addition, the market players are applying the market strategies such as product launches and collaboration to expand their business. For instance, in October 2021, bioMerieux - a French multinational biotechnology firm focusing on in-vitro diagnostics - launched predictive Diagnostics, the company's new offering in food safety and food quality. Also, in September 2022, QIAGEN and Neuron23 Inc., a biotechnology organization focused on designing precision medicines for genetically defined neurological and immunological diseases, agreed to create a companion diagnostic for Neuron23's brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson's disease. In this agreement, QIAGEN will design and validate a clinical trial assay that will detect a mixture of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson's disease to an LRRK2 inhibitor. Furthermore, this partnership will support the clinical development of Neuron23's drug candidate, which is presently in the late stages of preclinical development. Subject to further clinical development, the agreement also enfolds options for developing additional companion diagnostics.

The lack of expertise in predictive diagnostics testing will hamper the growth of the market

However, less reliability of biomarkers for identifying chronic degenerative diseases and lack of expertise in predictive diagnostics testing will restrain the market in the forecast period.

COVID-19 Impact Analysis

The appearance of COVID-19 positively impacted the global predictive diagnostics market. As per the article published in Advances in Biomarker Sciences and Technology in 2020, biomarkers are particularly important during a pandemic state since they can enhance the development and approval of new, innovative drugs and biological products, particularly in the field of vaccines. Biomarkers can be applied to describe observable characteristics of certain diseases and determine optimal treatments based on these phenotypes and genotypes; thence, they have received substantial attention. In particular, respiratory disease biomarkers, such as those associated with acute respiratory distress syndrome (ARDS), have been associated with increased mortality (IL-8, ICAM-1) and improved survival (nitric oxide). These biomarkers play a pivotal role in predicting future complications or disease severity and could be useful as an indicator for COVID-19 prognosis.

Segment Analysis

The oncology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The oncology segment accounts for the largest market share. Cancer is the foremost cause of death worldwide. The most familiar cancers are breast, colon, lung, rectum, and prostate. Cancer accounted for almost 10 million deaths in 2020 or nearly one in six.

As per the article published in Frontiers in Oncology in September 2022, predictive biomarkers in the context of progressive disease treated with chemotherapy are also included. A meta-analysis of clinicopathological features that predict necrosis/fibrosis in retroperitoneal residual masses of non-seminoma patients, including histopathological features in the orchiectomy specimen (absence of teratoma, presence of seminoma), as well as serum tumor markers (normal HCG and AFP, elevated LDH) and size of the mass (>50% change in size, smaller residual mass size). A

Also, identified features that predict the development of choriocarcinoma syndrome (a severe complication, challenging to treat and with considerable mortality) in poor-risk germ cell tumor patients, including metastatic lung involvement of more than half and ECOG PS around two. Rising cancer cases and demand for predictive diagnostics drives the market worldwide.

Geographical Analysis

North America region holds the largest market share of the global predictive diagnostics market

North America dominates the market for predictive diagnostics and is anticipated to show an equivalent trend over the forecast period. The market is driven by improved healthcare infrastructure, the increasing incidence of infectious disease, active regional key players, and easy availability of products in the region.

The market players are offering predictive diagnostics in the North American region. For instance, F. Hoffmann-La Roche Ltd provides predictive diagnostics solutions for oncology, cardiovascular disease, infectious disease, respiratory disease, autoimmune disease and more.

In addition, key players are adopting the market strategies such as acquisition and product launches. For instance, in December 2021, Roche acquired the TIB Molbiol Group. TIB Molbiol will continue to work as a subsidiary within the Diagnostics division. Roche and TIB Molbiol will create their capabilities for the fast development of assays for emerging pathogens and potential health threats, such as infectious diseases.

Competitive Landscape

The predictive diagnostics market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Abbott Molecular, Almac Group Ltd., Ambry Genetics Corporation, BioGenex, Epistem Ltd., F. Hoffmann-La Roche Ltd., Genomic Health, Inc., MDxHEALTH, Inc., Myriad Genetics, Inc., OPKO Health, Inc, Prometheus Laboratories Inc., Proteomics International Laboratories Ltd, and QIAGEN N.V., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the predictive diagnostics market globally.

For instance,

In September 2021, Janssen-a pharmaceutical subsidiary of Johnson & Johnson - introduced its nine-month startup accelerator - a program for the digital health startup space to gain innovative ideas on predictive diagnostics to discover precision treatments and therapies.

QIAGEN

Overview:

QIAGEN is a German organization founded in 1984 and headquartered in Hilden, Germany. It delivers the solutions for molecular testing and provides the answer from the building blocks of life- DNA, RNA, and protein to the customers to unblock the new insights.

Product Portfolio:

NextSeq 550Dx: This instrument is FDA-regulated and CE-in vitro diagnostic (IVD) marked, allowing clinical laboratories to design and execute a broad range of applications, from Next Generations sequencing solutions IVD assays using targeted panels to clinical research applications that include techniques from targeted panels to whole genomes.

The global predictive diagnostics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in prevalence of chronic diseases
      • 4.1.1.2. Increasing prevalence in various types of cancer
      • 4.1.1.3. Need for detection of various genetic disorders at the earliest stage
    • 4.1.2. Restraints:
      • 4.1.2.1. Less reliability of biomarkers
      • 4.1.2.2. Lack of expertise
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Presymptomatic*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Predispositional

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cardiovascular Diseases*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Neurological Diseases
  • 8.4. Genetic Diseases
  • 8.5. Oncology
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Diagnostics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Genetic Laboratories and Clinics
  • 9.4. Research and Academic Institutes

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Type Benchmarking

12. Company Profiles

  • 12.1. Abbott Molecular*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Almac Group Ltd.
  • 12.3. Ambry Genetics Corporation
  • 12.4. BioGenex
  • 12.5. Epistem Ltd.
  • 12.6. F. Hoffmann-La Roche Ltd.
  • 12.7. Genomic Health, Inc.
  • 12.8. MDxHEALTH, Inc.
  • 12.9. Myriad Genetics, Inc.
  • 12.10. OPKO Health, Inc.
  • 12.11. Prometheus Laboratories Inc.
  • 12.12. Proteomics International Laboratories Ltd
  • 12.13. QIAGEN N.V.

LIST NOT EXHAUSTIVE

13. Global Predictive Diagnostics Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us